JDJinhua Dong

Jinhua Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinhua Dong has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Chengjian Ai

    Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education

    2 shared publications
  • Guanyi Zhao

    Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education

    2 shared publications
  • Mengdi Xu

    Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education

    2 shared publications
  • Shaoshan Xu

    Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education

    2 shared publications
  • Tao Jiang

    Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education

    2 shared publications
  • Xiaosheng Jiang

    Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education

    2 shared publications

Latest Publications

  • Discovery of New Teraryl γ-Lactam Derivatives as Potent Antibacterial Agents In Vitro and In Vivo through Dual Cell Wall–Membrane Inhibitions

    by Lishu Sheng, Yue Yuan, Taopeng Chang, Yitong Hu, Fang Li, Zhifu Chen, Jingwen Liao, Dianyan Chen, Feifei Chen, Jinhua Dong, et al.

    Antimicrobial resistance threatens global public health, urgently requiring new antibiotics. Herein, we report a novel antibacterial scaffold with a 1,2,4-oxadiazole teraryl moiety and γ-lactam fragment via bacteria-based phenotypic screening. Diversified modifications of its four sites yielded 42 derivatives, and comprehensive SAR analysis against multidrug-resistant "superbugs" identified lead compound 8c. 8c exhibits excellent activity against drug-resistant Gram-positive bacteria (e.g., MRSA, VISA, VRE), 4-32-fold more potent than ciprofloxacin and meropenem. 8c shows rapid bactericidal activity, a low propensity to induce resistance, and a moderate safety profile. Mechanistically, 8c inhibits peptidoglycan biosynthesis by targeting the Lipid II cycle and disrupts membrane homeostasis via enhanced permeability and induced hyperpolarization, with this dual action validated by proteomic and lipidomic analyses. It also has excellent liver microsomal stability, favorable in vivo pharmacokinetics, and potent in vivo anti-MRSA efficacy. This novel scaffold is a promising addition to the antibiotic arsenal and warrants further development.

  • Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects

    by Shaoshan Xu, Xiaosheng Jiang, Tao Jiang, Chengjian Ai, Zhen Tian, Mengdi Xu, Guanyi Zhao, Yang Liu, Jingyi Zhang, Meihui Zhang, et al.

    Tropomyosin receptor kinase (TRK) is an important therapeutic target for tumors driven by NTRK gene fusions. However, the clinically approved TRK inhibitors, including Larotrectinib and Entrectinib, are limited by insufficient efficacy and resistance due to kinase mutations. Here, we report DZX19 (C02), a novel phenyl thiophene-3-carboxamide TRK inhibitor developed via a pharmacophore-guided scaffold-hopping approach combined with structure-based design, based on the key binding features of Entrectinib. DZX19 demonstrated stronger in vitro activity and an improved resistance profile against Entrectinib-resistant TRKA mutants, including G595R, F589L, and G667C. In the TPM3-NTRK1 fusion-positive Km-12 cell line, DZX19 induced G1 arrest, promoted apoptosis, and suppressed TRK downstream signaling. DZX19 displayed excellent plasma stability and moderate microsomal stability. In the Km-12 xenograft model, DZX19 significantly suppressed tumor growth. These results indicate that DZX19 serves as a novel TRK-targeting lead compound for further investigation.


  • Open Access

    Facile expression of proteins with desired N-terminal amino acid via an engineered cysteine protease domain

    by Xiangman Zou, Zhi Liu, Fengnan Song, Wei Zhou, Jiaying Hang, Chenchen Feng, Tianhong Yuan, Jinhua Dong, Wei Shi, Feng Tang, et al.

    The removal of N-terminal methionine (Met) or fused N-terminal purification tags to expose the first amino acid of the target protein is critically important for studying the potential regulatory role of the N-terminal residue. However, current tag-removal approaches typically rely on enzymatic cleavage or require harsh reaction conditions. Here, we report a strategy for expressing proteins of interest (POI) with custom N-terminal amino acids by introducing an engineered cysteine protease domain (CPD) tag at the N-terminus. The cleavable tag is chemically triggered by inositol hexakisphosphate (InsP6), enabling precise generation of proteins with a user-defined N-terminus. Through systemic design and engineering of the N-terminal CPD tag, we successfully achieved POI variants with N-terminal Gly, Ser, His, Lys and other residues except Pro. In addition to the model protein, a Her2-targeting nanobody, we also successfully produced a RNF43-specific nanobody with an N-terminal Gln (N-Gln), an EGFR-targeting nanobody with N-Ala, the Sortase A enzyme with N-Gln, the fluorescent protein TurboGFP with N-Glu, and the sialic acid transferase Δ15 Pd2,6ST with N-Cys. The construction of engineered nCPD-His10-POI further produced POI variants with a customized N-terminus and without any purified tags. Overall, the established approach enables high-yield protein expression and enzyme-independent, single-step removal of the redundant tag to yield proteins with the desired N-terminal residues, offering a valuable option for investigating N-terminal modifications and their functional implications.


  • Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK Inhibitors

    by Shaoshan Xu, Xiaosheng Jiang, Mengdi Xu, Chengjian Ai, Guanyi Zhao, Tao Jiang, Yang Liu, Zhen Tian, Meihui Zhang, Jinhua Dong


  • Open Access

    Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects

    by Yaping Liu, Yingying Huang, Guantao He, Chun Guo, Jinhua Dong, Linping Wu

    Lipid nanoparticles (LNPs) have emerged as leading non-viral carriers for messenger RNA (mRNA) delivery in clinical applications. Overcoming challenges in safe and effective mRNA delivery to target tissues and cells, along with controlling release from the delivery vehicle, remains pivotal in mRNA-based therapies. This review elucidates the structure of LNPs, the mechanism for mRNA delivery, and the targeted delivery of LNPs to various cells and tissues, including leukocytes, T-cells, dendritic cells, Kupffer cells, hepatic endothelial cells, and hepatic and extrahepatic tissues. Here, we discuss the applications of mRNA–LNP vaccines for the prevention of infectious diseases and for the treatment of cancer and various genetic diseases. Although challenges remain in terms of delivery efficiency, specific tissue targeting, toxicity, and storage stability, mRNA–LNP technology holds extensive potential for the treatment of diseases.